OverviewSuggest Edit
Smith & Nephew is an industry leader in each of our three main Global Business Units - Orthopaedic Reconstruction and Trauma, Endoscopy and Advanced Wound Management. These businesses jointly offer over 1,000 product ranges.
Our global infrastructure continues to expand each year. We currently operate in 32 countries and generate annual sales of $3.4 billion. Substantial investment in our products and intensive research and development means that we are always ahead. Figures from last year show that we stand at number one as the leading company in Arthroscopy. We are the second largest organisation in Advanced Wound Management and number three in Trauma and Clinical Therapies. We are also positioned at number four in reconstruction.
Smith & Nephew has a track record of bringing innovative new products to market that provide better clinical outcomes for patients and save costs for healthcare providers. This is the primary focus of our fourth business unit, Biologics.
... Show more| Type | Public | |
| Founded | 1856 | |
| HQ | London, GB | Map |
| Website | global.smith-nephew.com |
Recent NewsAll News
- Antimicrobial Wound Dressing Market Show High Growth Till 2026 With Emerging Players Smith & Nephew plc. ConvaTec Group plc. Medtronic plc., Acelity L.P. Inc., Coloplast A/S, Mölnlycke Health Care, Paul Hartmann AG
- UPDATE 1-Emerging markets to fuel Smith & Nephew revenue growth in 2019
- Smith & Nephew misses on Q4 revenue as developed markets slow
- Adhesive Bandages Global Market 2018: Key Players – Johnson & Johnson, Beiersdorf, 3M, Medline Industries, Smith & Nephew
Key People/Management at Smith & Nephew
Olivier Bohuon
Graham Baker
John W. Campo
Helen Maye
Philippe Mazas
Smith & Nephew Office Locations
Smith & Nephew Financials and Metrics
Smith & Nephew Revenue
| GBP | |
|---|---|
Revenue (FY, 2017) | 3.5b |
Gross profit (FY, 2017) | 2.6b |
Gross profit margin (FY, 2017), % | 73.8% |
Net income (FY, 2017) | 556.8m |
EBITDA (FY, 2017) | 993.8m |
EBIT (FY, 2017) | 678.0m |
Market capitalization (13-Feb-2019) | 33.3m |
Closing stock price (13-Feb-2019) | 0.4 |
Cash (31-Dec-2017) | 122.7m |
EV | (69.8m) |
- Source: Company Filings
| GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.1b | 1.0b | 1.1b | 1.1b | 1.1b | 1.1b | 1.1b | 1.2b | 1.2b | 1.4b | 1.4b | 2.0b | 2.9b | 3.2b | 3.6b | 3.4b | 3.5b |
Revenue growth, % | 11% | 0% | 13% | ||||||||||||||
Cost of goods sold | 472.6m | 446.1m | 453.3m | 479.6m | 456.8m | 350.2m | 329.9m | 345.1m | 334.8m | 361.0m | 1.1b | 600.7m | 724.8m | 797.5m | 883.4m | 923.3m | 905.9m |
Gross profit | 596.6m | 602.0m | 600.1m | 640.3m | 677.9m | 731.5m | 780.0m | 833.8m | 913.7m | 1.0b | 292.0m | 1.4b | 2.1b | 2.4b | 2.7b | 2.5b | 2.6b |
- Source: Company Filings
| GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 80.5m | 57.1m | 49.9m | 100.5m | 24.6m | 30.0m | 22.5m | 26.0m | 32.6m | 88.0m | 177.0m | 102.7m | 90.3m | 63.8m | 92.8m | 72.6m | 122.7m |
Accounts Receivable | 218.7m | 219.9m | 233.1m | 241.8m | 246.2m | 224.4m | 222.6m | 246.0m | 273.5m | 323.0m | 322.0m | 468.3m | 616.1m | 664.3m | 751.3m | 717.2m | 766.6m |
Inventories | 229.8m | 225.7m | 242.4m | 237.6m | 228.2m | 232.2m | 229.5m | 230.6m | 284.9m | 355.0m | 316.0m | 504.0m | 662.8m | 810.5m | 940.6m | 903.0m | 946.6m |
Current Assets | 564.5m | 561.3m | 570.9m | 619.2m | 530.6m | 525.4m | 532.7m | 591.1m | 679.3m | 937.0m | 840.0m | 1.2b | 1.5b | 1.7b | 1.9b | 1.8b | 2.0b |
| GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 120.7m | 113.7m | 93.7m | 104.8m | 205.2m | 129.6m | 112.1m | 148.1m | 125.2m | 170.0m | 201.0m | 191.0m | 366.3m | 343.8m | 316.9m | 569.1m | 556.8m |
Cash From Operating Activities | 189.3m | 181.7m | 161.9m | 198.1m | 204.0m | 191.9m | 209.3m | 214.5m | 226.6m | 147.0m | 190.0m | 264.7m | 571.3m | 468.7m | 796.1m | 616.3m | 791.2m |
Dividends Paid | 66.5m | 69.0m | 69.2m | 72.5m | 456.9m | 42.9m | 44.6m | 46.1m | 47.8m | 50.0m | 49.0m | 62.8m | 157.5m | 164.0m | 202.5m | 195.3m | |
Cash From Financing Activities | 40.4m | (19.7m) | 158.7m | 17.8m | 94.8m | (93.1m) | (16.9m) | (22.0m) | (196.0m) | 209.7m | (328.1m) | 691.8m | (431.3m) | (384.0m) | (315.0m) |
| GBP | Y, 2017 |
|---|---|
EV/EBITDA | -0.1 x |
EV/EBIT | -0.1 x |
EV/CFO | -0.1 x |
Revenue/Employee | 228.4k |
Financial Leverage | 1.7 x |
Smith & Nephew Operating Metrics
| FY, 2016 | |
|---|---|
Training Provided, no. of people | 90 k |
Smith & Nephew Revenue Breakdown
Smith & Nephew revenue breakdown by business segment: 12.9% from Sports Medicine Joint Repair , 13.9% from Arthroscopic Enabling Technologies , 9.9% from Trauma & Extremities, 19.8% from Knee Implants, 12.9% from Hip Implants, 14.9% from Advanced Wound Care, 6.9% from Advanced Wound Bioactives and 8.9% from Other
Smith & Nephew Online and Social Media Presence
3.81k Twitter followers
Smith & Nephew has 3.81k Twitter Followers. The number of followers has increased 1.2% month over month and increased 4.7% quarter over quarter
Smith & Nephew News and Updates
Antimicrobial Wound Dressing Market Show High Growth Till 2026 With Emerging Players Smith & Nephew plc. ConvaTec Group plc. Medtronic plc., Acelity L.P. Inc., Coloplast A/S, Mölnlycke Health Care, Paul Hartmann AG
UPDATE 1-Emerging markets to fuel Smith & Nephew revenue growth in 2019
Smith & Nephew misses on Q4 revenue as developed markets slow
Adhesive Bandages Global Market 2018: Key Players – Johnson & Johnson, Beiersdorf, 3M, Medline Industries, Smith & Nephew
Bio Implant 2019 Global Market Key Players - Abbot Laboratories, Boston Scientific, Johnson & Johnson, Philips, Medtronic, C.R. Bard, Edwards Lifesciences, Bausch & Lomb Incorporated, Smith & Nephew......
Surgical Drainage Devices 2019 Global Market Key Players – B. Braun Melsungen, Smith & Nephew, Medtronic, Acelity, Integra LifeSciences, Teleflex Incorporated, Stryker Corporation, Johnson & Johnson, C. R. Bard – Analysis and Forecast to 2025
Smith & Nephew Company Life and Culture
Smith & Nephew Frequently Asked Questions
When was Smith & Nephew founded?
Smith & Nephew was founded in 1856.
Who are Smith & Nephew key executives?
Smith & Nephew's key executives are Olivier Bohuon, Graham Baker and John W. Campo.
How many employees does Smith & Nephew have?
Smith & Nephew has 15,000 employees.
What is Smith & Nephew revenue?
Latest Smith & Nephew annual revenue is £3.5 b.
What is Smith & Nephew revenue per employee?
Latest Smith & Nephew revenue per employee is £230.6 k.
Who are Smith & Nephew competitors?
Competitors of Smith & Nephew include Stryker, Integer Holdings and Advanced Biomedical Technologies.
Where is Smith & Nephew headquarters?
Smith & Nephew headquarters is located at 15 Adam Street, London.
Where are Smith & Nephew offices?
Smith & Nephew has offices in London, São Paulo, Memphis, Fort Worth and in 4 other locations.
How many offices does Smith & Nephew have?
Smith & Nephew has 8 offices.